Avalo Therapeutics outlines 2026 board changes

Avalo Therapeutics, Inc. reported that two members of its board of directors, Dr. Jonathan Goldman and Mitchell Chan, have decided not to stand for re-election at the company’s 2026 Annual Meeting of Stockholders.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. reported that two members of its board of directors, Dr. Jonathan Goldman and Mitchell Chan, have decided not to stand for re-election at the company’s 2026 Annual Meeting of Stockholders. Both directors will continue serving on the board until that meeting.

The company stated that their decisions are not the result of any disagreement with Avalo on matters related to operations, policies, or practices. The board expressed its appreciation to Dr. Goldman and Mr. Chan for their service and contributions.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board changes did Avalo Therapeutics (AVTX) disclose in this 8-K?

Avalo Therapeutics disclosed that directors Dr. Jonathan Goldman and Mitchell Chan have decided not to stand for re-election at the 2026 Annual Meeting. Both will continue serving on the board until that meeting before their terms end.

Are the Avalo Therapeutics (AVTX) director departures due to disagreements?

No. Avalo Therapeutics stated that the decisions by Dr. Goldman and Mr. Chan not to stand for re-election are not the result of any disagreement regarding the company’s operations, policies, or practices, indicating these are orderly, non-contentious board transitions.

When will the Avalo Therapeutics (AVTX) directors leave the board?

Both Dr. Jonathan Goldman and Mitchell Chan will continue serving as directors until Avalo Therapeutics’ 2026 Annual Meeting of Stockholders. At that meeting, they will not stand for re-election and their board service will conclude.

Who signed the Avalo Therapeutics (AVTX) 8-K about board changes?

The 8-K was signed on behalf of Avalo Therapeutics by Christopher Sullivan, the company’s Chief Financial Officer, dated March 27, 2026. His signature confirms the company’s authorization and responsibility for the disclosed board transition information.

What exchange is Avalo Therapeutics (AVTX) common stock listed on?

Avalo Therapeutics’ common stock, with a par value of $0.001, is listed on the Nasdaq Capital Market under the trading symbol AVTX, as indicated in the company’s securities registration details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/27/2026 - 04:01 PM Learn about SEC filing dates

0001534120false00015341202026-03-232026-03-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2026

AVALO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)  

Delaware

(State or other jurisdiction of incorporation)

001-37590						45-0705648
(Commission File Number)						(IRS Employer Identification No.)

1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087

(Address of principal executive offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (410) 522-8707

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 Par Value			AVTX			Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02    Departure of Directors or Certain Officers; Election of Directors.

On March 23, 2026, Dr. Jonathan Goldman and Mitchell Chan, members of the board of directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”), each notified the Company of his decision to not stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Dr. Goldman and Mr. Chan will each continue to serve as a member of the Board until the 2026 Annual Meeting. Their decisions not to stand for re-election are not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. The Board thanks Mr. Chan and Dr. Goldman for their service and contributions.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									AVALO THERAPEUTICS, INC.
Date: March 27, 2026						By:			/s/ Christopher Sullivan
									Christopher Sullivan
									Chief Financial Officer

2

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2.1 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 14.2 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 24.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 14.7 KB